Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY2862789 |
Synonyms | |
Therapy Description |
BAY2862789 is a DGK-alpha inhibitor, which may increase TCR signaling and enhance antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY2862789 | BAY 2862789|BAY-2862789 | BAY2862789 is a DGK-alpha inhibitor, which may increase TCR signaling and enhance antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05858164 | Phase I | BAY2862789 | A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | ESP | AUS | 3 |